Current Cardiology Reports

, Volume 12, Issue 6, pp 450–463

Have the Renin-Angiotensin-Aldosterone System Perturbations in Cardiovascular Disease Been Exhausted?

Article

DOI: 10.1007/s11886-010-0140-7

Cite this article as:
Mansur, S.J., Hage, F.G. & Oparil, S. Curr Cardiol Rep (2010) 12: 450. doi:10.1007/s11886-010-0140-7

Abstract

The renin-angiotensin-aldosterone system (RAAS) plays an important role in blood pressure control and volume homeostasis. Inappropriate activation of the RAAS has been implicated in the pathogenesis of hypertension and related cardiovascular disease. Several classes of agents that block RAAS signaling have been shown to be effective antihypertensives and to have cardioprotective and renoprotective properties. Because blockade of the RAAS is incomplete with any of the currently available monotherapies, combinations of these agents have been tested and shown to provide additional clinical benefit in patients with hypertension and various forms of cardiovascular and renal disease.

Keywords

Renin-angiotensin systemHypertensionCardiovascular diseaseNephropathyHeart failure

Clinical Trial Acronyms

ALLAY

Aliskiren in Left Ventricular Hypertrophy

ALOFT

Aliskiren Observation of Heart Failure Treatment

ALTITUDE

Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints

ASCOT-BPLA

Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm

ASPIRE

Aliskiren Study in Post-MI Patients to Reduce Remodeling

ATMOSPHERE

Aliskiren Trial to Minimize Outcomes in Patients with Heart Failure

AVOID

Aliskiren in the Evaluation of Proteinuria in Diabetes

CALM

Candesartan and Lisinopril Microalbuminuria

CHARM

Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity

EPHESUS

Eplerenone Post-AMI Heart Failure Efficacy and Survival Study

HOPE

Heart Outcomes Prevention Evaluation

IMPROVE

Irbesartan Versus Placebo in Combination with Ramipril for Treatment of Albuminuria

ONTARGET

Ongoing Telmisartan Alone and in Combination with Ramipril Global End Point Trial

RALES

Randomized Aldactone Evaluation Study

RESOLVD

Randomized Evaluation of Strategies for Left Ventricular Dysfunction

TRANSCEND

Telmisartan Randomised Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease

Val-HeFT

Valsartan Heart Failure Trial

VALIANT

Valsartan in Acute Myocardial Infarction

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Sulaf J. Mansur
    • 4
  • Fadi G. Hage
    • 1
    • 2
    • 3
  • Suzanne Oparil
    • 5
  1. 1.BirminghamUSA
  2. 2.Division of Cardiovascular DiseasesUniversity of Alabama at BirminghamBirminghamUSA
  3. 3.Section of CardiologyBirmingham Veteran’s Administration Medical CenterBirminghamUSA
  4. 4.Jefferson Clinic PCBirminghamUSA
  5. 5.Division of Cardiovascular DiseasesUniversity of Alabama at BirminghamBirminghamUSA